The FLT3/FLK2 ligand: Structure, functions and prospects

European Cytokine Network

Volumn 9, Issue 1, 1998, Pages 7-22

  Fichelson, Serge ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Lab de Rech d'Hemobiologie Cochin   (France)

Author keywords

Dendritic cells; Expansion; FLT3 ligand; FLT3 receptor; Hematopoietic stem cells; Mobilization; Progenitors

Indexed keywords

CYTOKINE RECEPTOR; HEMOPOIETIC GROWTH FACTOR;

DENDRITIC CELL; GENE DISRUPTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOLECULAR CLONING; PROTEIN EXPRESSION; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; HEMATOPOIESIS; HUMANS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0031961384     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Metcalf D. 1993. Hematopoietic regulators: Redundancy or subtlety. (Review) Blood 82: 3515.
2. Ogawa M. 1993. Differentiation and proliferation of hematopoietic stem cells. (Review) Blood 81: 2844.
3. Eaves C J, Cashman J D, Kay R J, Dougherty G J, Otsuka T, Gaboury L A, Hogge D E, Lansdorp P M, Eaves A C, Humphries R K. 1991. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term hone marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. Blood 78: 110.
4. Verfaillie C M. 1993. Soluble factor(s) produced by human hone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation. Blood 82: 2045.
5. Simmons P J, Zannettino A, Gronthos S, Leavesley D. 1994. Potential adhesion mechanisms for localisation of hematopoietic progenitors to bone marrow stroma. (Review) Leuk. Lymphoma 12: 353.
6. + HLA-DR bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis. (Review) Blood Cells 17: 287.
7. +, CD38 hematopoietic stem cells. Blood 83: 1515.
8. Berardi A C, Wang A, Levine J D, Lopez P, Scadden D T. 1995. Functional isolation and characterization of human hematopoietic stem cells. Science 267: 104.
9. Goodell M A, Rosenzweig M, Kim H, Marks D F, DeMaria M, Paradis G, Grupp S A, Sieff C A, Mulligan R C, Johnson R P. 1997. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetecable levels of CD34 antigen exist in multiple species. Nature Medicine 3: 1337.
10. Broudy V C. 1997. Stem cell factor and hematopoiesis. (Review) Blood 90: 1345.
11. Yarden Y, Kuang W J, Yang-Feng T L, Coussens L, Munemitsu S, Dull T J, Chen E, Schlessinger J, Francke U, Ullrich A. 1997. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6: 3341.
12. Sherr C, Rettenmeier C, Sacca R, Roussel M, Look A, Stanley E. 1985. The c-fins proto-oncogene product is related to the receptor for mononuclear phagocyte factor, CSF-1. Cell 41: 665.
13. Matthews W, Jordan C T, Wiegand G W, Pardoll D, Lemischka I R. 1991. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65: 1143.
14. Rosnet O, Marchetto S, de Lapeyrière O, Birnbaum D. 1991. Murine flt3, a gene encoding a novel kinase receptor of the PDGFR/CSFIR family. Oncogene 6: 1641.
15. Claesson-Welsh L. 1994. Platelet-derived growth factor receptor signals. (Review) J. Biol. Chem. 269: 32023.
16. Rosnet O, Mattéi M G, Marchetto S, Birnbaum D. 1991. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics 9: 380.
17. Rosnet O, Stephenson D, Mattéi M G, Marchetto S, Shibuya M, Chapman V M, Birnbaum D. 1993. Close physical linkage of the flt1 and flt3 genes on chromosome 13 in man and chromosome 5 in mouse. Oncogene 8: 173.
18. Wang Z, Kim E, Chinault A C, Civin C I, Small D. 1996. Genomic organization of the human STK1 (flt3/flk2) gene. ASH Meeting: 3170.
19. Liu C, Wang Z, Kim B, Friedman A, Civin C, Small D. 1997. Characterization of the human STK-1/FLT3/FKL2 promoter. ASH Meeting: 1355.
20. Lyman S D, James L, Zappone J, Sleath P, Beckmann P, Bird T. 1993. Characterization of the protein encoded by the flt3 (flt2) receptor-like tyrosine kinase gene. Oncogene 8: 815.
21. Lavagna C, Marchetto S, Birnbaum D, Rosnet O. 1995. Identification and characterization of a functional murine FLT3 isoform produced by exon skipping. J. Biol. Chem. 270: 3165.
22. Zeigler F C, Bennet B D, Jordan C T, Spencer S D, Baumhueter S, Carrol K J, Hooley J, Bauer K, Matthews W. 1994. Cellular and molecular characterization of the role of the Flk2/Flt3 receptor tyrosine kinase in hematopoietic stem cells. Blood 84: 2422.
23. Dosil M, Wang S, Lemischka IR. 1993. Mitogenic signalling and substrate specificity of the FlK2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin-3-dependent hematopoietic cells. Mol. Cell Biol. 13: 6572.
24. Rottapel R, Turck C W, Casteran N, Liu X, Birnbaum D, Pawson T, Dubreuil P. 1994. Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of murine Flt3 receptor tyrosine kinase. Oncogene 9: 1755.
25. Casteran N, Rottapel R, Beslu N, Lecoq E, Birnbaum D, Dubreuil P. 1994. Analysis of the mitogenic pathway of the FLT3 receptor and characterization in its C terminal region of a specific binding site for PI3′ kinase. Cell Mol. Biol. (Noisy-le-Grand) 40: 443.
26. Lavagna-Sévenier C, Marchetto S, Birnbaum D, Rosnet O. Flt3 signalling in hematopoietic cells involves CBL, SHC and an unknown p115 as prominent tyrosine-phosphorylated substrates. Leukemia. In press.
27. Beslu N, LaRose J, Casteran N, Birnbaum D, Lecocq E, Dubreuil P, Rottapel R. 1996. Phosphatidylinositol-3′ kinase is not required for mitogenesis or internalization of the Flt3/FlK2 receptor tyrosine kinase. J. Biol. Chem. 271: 20075.
28. De Lapeyrière O, Naquet P, Planche J, Marchetto S, Rottapel R, Gambarelli D, Rosnet O, Birnbaum D. 1995. Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissues. Differentiation 58: 351.
29. Rosnet O, Schiff C, Pébusque M, Marchetto S, Tonnelle C, Toiron Y, Birg F, Birnbaum D. 1993. Human flt3/flk2 gene: cDNA cloning and expression in hematopoietic cells. Blood 82: 1110.
30. Testa U, Fossati C, Samoggia P, Masciulli R, Mariani G, Hassan H J, Sposi N M, Guerriero R, Rosato V, Gabbianelli M, Pelosi E, Valtieri M, Peschle C. 1996. Expression of growth factor receptors in unilineage differentiation culture of purified hematopoietic progenitors. Blood 88: 3391.
31. Turner A M, Lin N L, Issarachai S, Lyman S D, Broudy V C. 1996. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 88: 3383.
32. Rappold I, Ziegler B L, Köhler I, Marchetto S, Rosnet O, Birnbaum D, Simmons P J, Zannettino A C W, Hill B, Neu S, Knapp W, Alitalo R, Alitalo K, Ullrich A, Kanz L, Bühring H J. 1997. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood 90: 111.
33. Mackarehtschian K, Hardin J D, Moore K A, Boast S, Goff S P, Lemischka I R. 1995. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3: 147.
34. Besmer P, Manova K, Duttlinger R, Huang E J, Packer A, Gyssler C, Bachvarova R F. 1993. The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis. (Review) Dev. suppl. 125.
35. Meierhoff G, Dehmel U, Gruss H J, Rosnet O, Birnbaum D, Dirks N, Drexler H G. 1995. Expression of the FLT3 receptor and FLT3 ligand in human leukemia-lymphoma cell lines. Leukemia 9: 1368.
36. Brasel K, Escobar S, Anderberg R, de Vries P, Gruss H J, Lyman S D. 1995. Expression of the FLT3 receptor and its ligand on hematopoietic cells. Leukemia 9: 1212.
37. Dehmel U, Quentmeier H, Drexler H G. 1996. Effects of FLT3 ligand on human leukemia cells. II. Agonistic and antagonistic effects of other cytokines. Leukemia 10: 271.
38. Eder M, Hemmati P, Kalina U, Ottman O G, Hoelzer D, Lyman S D, Ganser A. 1996. Effects of FLT3 ligand and interleukin-7 on in vitro growth of acute lymphoblastic leukemia cells. Exp. Hematol. 24: 371.
39. Rosnet O, Bühring H J, Marchetto S, Rappold I, Lavagna C, Sainty D, Arnoulet C, Chabannon C, Kantz L, Hannum C, Birnbaum D. 1996. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10: 238.
40. Drexler H G. 1996. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. (Review) Leukemia 10: 588.
41. Begley C G, Rasko J E, Curtis D, Takagi K, Metcalf D, Hilton D, Roberts B, Nicola N A, Rossner M T. 1996. Murine FLT3 ligand protects M1 leukemic cells from LIF-induced differentiation and suppression of self-renewal. Exp. Hematol. 24: 1247.
42. Birg F, Courcoul M, Rosnet O, Bardin F, Pébusque M J, Marchetto S, Tabilio A, Mannoni P, Birnbaum D. 1992. Expression of the FMS/KIT-like gene flt3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 80: 2584.
43. Rappold I, Rosnet O, Birnbaum D, Kanz L, Bühring H J. 1995. The FLT3/FLK2 receptor tyrosine kinase is a cell surface protein expressed on defined subsets of normal human bone marrow cells and on leukemic blasts from patients with ALL and AML. Blood 86: 145a.
44. Schwinzer B, Schrappe M, Bühring H S, Reiter A, Wittner N, Riehn M J, Welte K. 1995. Expression of receptor tyrosine kinase on lymphoblasts is related to the risk in childhood acute lymphoblastic leukemia. Blood 86: 176 a.
45. McKenna H J, Smith F O, Brasel K, Hirschstein D, Bernstein I D, Williams D E, Lyman S D. 1996. Effects of FLT3 ligand on acute myeloid and lymphocytic leukemic blast cells from children. Exp. Hematol. 24: 378.
46. Dehmel U, Zaborski M, Meierhoff G, Rosnet O, Birnbaum D, Ludwig W D, Quentmeier H, Drexler H G. 1996. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. Leukemia 10: 261.
47. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S. 1996. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10: 1911.
48. Stacchini A, Fubini L, Severino A, Sanavio F, Aglietta M, Piacibello W. 1996. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. Leukemia 10: 1584.
49. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M. 1996. FLT3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 88: 3987.
50. Serve H, Fenski R, Flesch K, Serve S, Günther J, Neuloh M, Thiel E, Berdel W E. 1997. Constitutive activation of FLT3 by point mutation in the kinase domain confers factor-independence of 32D cells. ASH Meeting: 1441.
51. Serve H, Flesch K, Fenski R, Serve S, Schwartz S, Günther J, Neuloh M, Thiel E, Berdel W E. 1997. Ligand-independent autophosphorylation of FLT3 in leukemic blasts of patients with ANLL. ASH Meeting: 3612.
52. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kahsima K, Matsuo Y, Naoe T. 1997. Internal tandem duplication of the flt3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11: 1605.
53. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, Takeshita A, Saito K, Hasegawa S, Shimodaira S, Tamura J, Shimazaki C, Matsue K, Kobayashi H, Arima N, Suzuki R, Morishita H, Saito H, Ueda R, Ohno R. 1997. Internal tandem duplication of FLT3 associated with leucocytosis in acute promyelocytic leukemia. Leukemia 11: 1447.
54. Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H, Taniwaki M, Kashima K, Fujii H, Abe T, Misawa S. 1997. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 11: 1441.
55. Iwai T, Yokota S, Nakao M, Kaneko H, Nakai H, Kashima K, Misawa S. 1997. Internal tandem duplication in the juxtatransmembrane domain of the FLT3 in not involved in blastic crisis of chronic myeloid leukemia. Leukemia 11: 1992.
56. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth L T, Picha K S, McKenna H J, Splett R R, Fletcher F A, Maraskovsky E, Farrah T, Foxworth D, Williams D E, Beckmann M P. 1993. Molecular cloning of a ligand for the flt3/flk2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75: 1157.
57. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan J F, Kastelein R, Hudak S, Wagner J, Mattson J, Luh J, Duda G, Martina N, Peterson D, Menon S, Shanafelt A, Muench M, Keiner G, Namikawa R, Rennick D, Roncarolo M G, Zlotnik A, Rosnet O, Dubreuil P, Birnbaum D, Lee F. 1994. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 368: 643.
58. Lyman S D, James L, Johnson L, Brasel K, de Vries P, Escobar S S, Downey H, Splett R R, Beckmann M P, McKenna H J. 1994. Cloning of the human homologue of the murine FLT3 ligand: a growth factor for early hematopoietic progenitor cells Blood 83: 2795.
59. Lyman S D, James L, Escobar S, Downey H, de Vries P, Brasel K, Stocking K, Beckmann M P, Copeland N G, Cleveland L S, Jenkins N A, Belmont J W, Davison B L. 1995. Identification of soluble and membrane-bound isoforms of the murine FLT3 ligand by alternative splicing of mRNAs. Oncogene 10: 149.
60. Lyman S D, Stocking K, Davison B, Fletcher F, Johnson L, Escobar S. 1995. Structural analysis of human and murine FLT3 ligand genomic loci. Oncogene 11: 1165.
61. Bazan J F. 1991. Genetic and structural homology of stem cell factor and macrophage colony-stimulating factor. (Letter) Cell 65: 9.
62. d mutant. Cell 64: 1025.
63. Toksoz D, Zsebo K M, Smith K A, Hu S, Brankow D, Suggs S V, Martin F H, Williams D A. 1992. Support of human hematopoiesis in long term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proc. Natl. Acad. Sci. USA 89: 7350.
64. McClanahan T, Culpepper J, Campbell D, Wagner J, Franz-Bacon K, Mattson J, Tsai S, Luh J, Guimaraes M J, Mattei M G, Rosnet O, Birnbaum D, Hannum C H. 1996. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand. Blood 88: 3371.
65. Lisovsky M, Braun S E, Ge Y, Takahira H, Lu L, Savchenko V G, Lyman S D, Broxmeyer H E. 1996. FLT3 ligand production by human bone marrow stromal cells. Leukemia 10: 1012.
66. Lyman S D, Seaberg M, Hanna R, Zappone J, Brasel K, Abkowitz J L, Prchal J, Schultz J, Shahidi N T. 1995. Plasma/serum levels of Flt3 ligand are low in normal individuals and are highly elevated in patients with Fanconi anemia and acquired aplastic anemias. Blood 86: 4091.
67. Wodnar-Filipowicz A, Lyman S D, Gralwohl A, Tichelli A, Speck B, Nissen C. 1996. FLT3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood 88: 4493.
68. Todd G, Haug J S, Bremer R, Link D, Goodnough L, Adkin D, Brown R, DiPersio J. 1997. FLT3 ligand levels vary before and during G-CSF administration. ASH Meeting: 931.
69. Kojima S, Matjuyama T, Kodera Y. 1997. Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anaemia. Br. J. Haematol. 99: 440.
70. McKenna H J, Miller R E, Brasel K, Maraskovsky E, Maliszewski C, Pulendran B, Lynch D, Teepe M, Roux E R, Smith J, Williams D E, Lyman S D, Peschon J J, Stocking K. 1996. Targeted disruption of the FLT3 ligand gene in mice affects multiple hematopoietic lineages, including natural killer cells, B lymphocytes, and dendritic cells. ASH Meeting: 1883.
71. Jacobsen S E W, Okkenhaug C, Myklebust J, Veiby O P, Lyman S D. 1995. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL)-11, IL-12, and other hematopoietic growth factors. J. Exp. Med. 181: 1357.
72. Yonemura Y, Ku H, Lyman S D, Ogawa M. 1997. In vitro expansion of hematopoietic progenitors and maintenance of stem cells: comparison between FLT3/FLK2 ligand and KIT ligand. Blood 89: 1915.
73. Veiby O P, Jaeobsen F W, Cui L, Lyman S D, Jaeobsen S E. 1997. The Flt3 ligand promotes the survival of primitive hematopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. Adv. Exp. Med. Biol. 417: 115.
74. Broxmeyer H E, Lu L, Cooper S, Ruggieri L, Li Z H, Lyman S D. 1995. FLT3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp. Hematol. 23: 1121.
75. + blood progenitors expressing different levels of c-kit protein. Eur. J. Haematol. 58: 257.
76. Piacibello W, Garetto L, Sanavio F, Severino A, Fubini L, Stacchini A, Dragonetti G, Aglietta M. 1996. The effects of human FLT3 ligand on in vitro human megakaryocytopoiesis. Exp. Hematol. 24: 340.
77. Namikawa R, Muench M O, Roncarolo M G. 1996. Regulatory roles of the ligand for FlK2/Flt3 tyrosine kinase receptor on human hematopoiesis. (Review) Stem Cells 14: 388.
78. +CD38) human hematopoietic cells: novel responses to Flt3 ligand and thrombopoietin. J. Exp. Med. 183: 2551.
79. Gabbianelli M, Pelosi E, Montesoro M, Valtieri M, Luchetti L, Samoggia P, Vitelli L, Barberi T, Testa U, Lyman S, Peschle C. 1995. Multi-level effects of FLT3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitor/monocytic precursors. Blood 86: 1661.
80. + cells. Blood 90: 3903.
81. Koller M R, Oxender M, Brott D A, Palsson B O. 1996. Flt3 ligand is more potent than c-kit ligand for the synergistic stimulation of ex vivo hematopoietic cell expansion. J. Hematother. 5: 449.
82. Piacibello W, Sanavio F, Garetto L, Severino A, Bergandi D, Ferrario J, Fagioli F, Berger M, Aglietta M. 1997. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 89: 2644.
83. +CD38 cells and maintains progenitor cells in vitro. Blood 87: 3563.
84. Muench M O, Roncarolo M G, Menon S, Xu Y, Kastelein R, Zurawski S, Hannum C H, Culpepper J, Lee F, Namikawa R. 1995. FLK2/FLT3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver. Blood 85: 963.
85. + hematopoietic progenitor cells. Blood 86: 3413.
86. +++ human umbilical cord blood myeloid progenitors in serum-depleted culture medium. Ann. Hematol. 72: 131.
87. +CD38 bone marrow cells with multilineage potential at the single-cell level: key role of thrombopoietin. Blood 90: 2282.
88. Hjertson M, Sundstrom C, Lyman S D, Nilsson G. 1996. Stem cell factor, but not flt3 ligand, induces differentiation and activation of human mast cells. Exp. Hematol. 24: 748.
89. Haylock D N, Horsfall M J, Dowse T L, Ramshaw H S, Niutta S, Protopsaltis S, Peng L, Burrell C, Rappold I, Buhring H J, Simmons P J. 1997. Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand. Blood 90: 2260.
90. + bone marrow progenitor cells in vitro. Blood 87: 1317.
91. Ohmizono Y, Sakabe H, Kimura T, Tanimukai S, Matsumura T, Miyazaki H, Lyman S D, Sonoda Y. 1997. Thrombopoietin augments ex vivo expansion of human cord blood with stem cell factor and FLT3 ligand. Leukemia 11: 524.
92. + progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction. Blood 89: 446.
93. - cell production in vitro. Br. J. Haematol. 98: 528.
94. Zandstra P W, Conneally E, Petzer A L, Piret J M, Eaves C J. 1997. Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc. Natl. Acad. Sci. USA. 94: 4698.
95. Ramsfjell V, Borge O J, Veiby O P, Cardier J, Murphy M J Jr, Lyman S D, Lok S, Jacobsen S E. 1996. Thrombopoietin, but not erythropoietin, directly stimulates multilineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: distinct interactions with the ligands for c-kit and FLT3. Blood 88: 4481.
96. Solar G, Chen Q, de Sauvage F, Eaton D, Cohen B. 1997. In vitro expansion of early hematopoietic progenitors by FLT3 ligand, kit ligand and TPO. ASH Meeting: 2111.
97. -) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and FLT3, and inhibitory effects of TGF-beta and TNF-alpha. J. Immunol. 158: 5169.
98. + hematopoietic progenitors elicited from human fetal liver, umbilical cord blood, bone marrow, and mobilized peripheral blood. J. Hematother. 5: 655.
99. Brashem-Stein C, Flowers D A, Bernstein I D. 1996. Regulation of colony forming cell generation by FLT3 ligand. Br. J. Haematol. 94: 17.
100. + human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl. Acad. Sci. USA 91: 459.
101. Ohishi K, Katayama N, Itoh R, Mahmud N, Miwa H, Kita K, Minami N, Shirakawa S, Lyman S D, Shiku H. 1996. Accelerated cell-cycling of hematopoietic progenitors by the FLT3 ligand that is modulated by transforming growth factor-beta. Blood 87: 1718.
102. Yang M, Li K, You F W, Yuen P M P. 1997. Lack of stimulative effect of FLT3 ligand on megakaryocytopoiesis. ASH Meeting: 3466.
103. Namikawa R, Muench M O, de Vries J E, Roncarolo M G. 1996. The FLK2/FLT3 ligand synergizes with interleukin-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells in vitro. Blood 87: 1881.
104. Faust E A, Saffran D C, Toksoz D, Williams D A, Witte O N. 1993. Distinctive growth requirements and gene expression patterns distinguish progenitor B cells from pre-B cells. J. Exp. Med. 177: 915.
105. Rawlings D J, Quan S G, Kato R M, Witte O N. 1995. Long-term culture system for selective growth of human B cell progenitors. Proc. Natl. Acad. Sci. USA 92: 1570.
106. +CD38 cord blood stem cells into B cell progenitors in vitro. Exp. Hematol. 25: 66.
107. Veiby O P, Lyman S D, Jacobsen S E. 1996. Combined signaling through interleukin-7 receptors and flt3 but not c-kit potently and selectively promotes B cell commitment and differentiation from uncommitted murine bone marrow progenitor cells. Blood 88: 1256.
108. Ray R J, Paige C J, Furlonger C, Lyman S D, Rottapel R. 1996. Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur. J. Immunol. 26: 1504.
109. Hirayama F, Lyman S D, Clark S C, Ogawa M. 1995. The Flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood 85: 1762.
110. Hunte B E, Hudak S, Campbell D, Xu Y, Rennick D. 1996. flk2/flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors. J. Immunol. 156: 489.
111. Moore T A, Zlotnik A. 1997. Differential effects of Flk2/Flt3 ligand and stem cell factor on murine thymic progenitor cells. J. Immunol. 158: 4187.
112. (-) cells from multipotential murine bone marrow progenitors in a stromal-free culture: definition of cytokine requirements and developmental intermediates. J. Exp. Med. 186: 1609.
113. Maraskovsky E, Brasel K, Teepe M, Roux E R, Lyman S D, Shortman K, McKenna H J. 1996. Dramatic-increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184: 1953.
114. Hart D N J. 1997. Dentritic cells: unique leukocyte populations which control the primary immune response. Blood 90: 3245.
115. + blood progenitors for anti-cancer therapy. Exp. Hematol. 23: 1463.
116. Strobl H, Bello-Fernandez C, Riedl E, Pickl W F, Majdic O, Lyman S D, Knapp W. 1997. Flt3 ligand in cooperation with transforming growth factor-β1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 90: 1425.
117. + cord blood cells under serum-free conditions. Hum. Gene. Ther. 8: 1651.
118. + PBPC in serum-free medium. ASH Meeting: 2125.
119. Brossart P, Grünebach F, Stuhler G, Möhle R, Stevanovic S, Rammensee H G, Kanz L, Brugger W. 1997. Generation of dendritic cells from peripheral blood monocytes in the absence of GM-CSF with FLT3 ligand and CD40 ligand. ASH Meeting: 1995.
120. Saunders D, Lucas K, Ismaili J, Wu L, Maraskovsky E, Dunn A, Shortman K. 1996. Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte/ macrophage colony-stimulating factor. J. Exp. Med. 184: 2185.
121. Shurin M R, Pandharipande P P, Zorina T D, Haluszczak C, Subbotin V M, Hunter O, Brumfield A, Storkus W J, Maraskovsky E, Lotze M T. 1997. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol. 179: 174.
122. Drakes M L, Lu L, Subbotin V M, Thomson A W. 1997. In vivo administration of FLT3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver. J. Immunol. 159: 4268.
123. Metcalf D, Shortman K, Vremec D, Mifsud S, Di Rago L. 1996. Effects of excess GM-CSF levels on hematopoiesis and leukemia development in GM-CSF/max 41 double transgenic mice. Leukemia 10: 713.
124. Zola H, Siderius N, Flego L, Beckman I, Seshadri R. 1994. Cytokine receptor expression in leukaemic cells. Leuk. Res. 18: 347.
125. Piacibello W, Fubini L, Sanavio F, Brizzi M F, Severino A, Garetto L, Stacchini A, Pegoraro L, Aglietta M. 1995. Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. Blood 86: 4105.
126. Drexler H G, Meyer C. 1997. FLT3 ligand promotes survival and inhibits apoptosis of myeloid leukemia cell lines. ASH Meeting: 3437.
127. Petzer A L, Eaves C J, Barnett M J, Eaves A C. 1997. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 90: 64.
128. Mahon F X, Pigeonnier-Lagarde V, Chahine H, Barbot C, Jazwiec B, Ripoche J, Reiffers J. 1997. Ex vivo cytokine expansion of peripheral blood 5-fluorouracil-treated CD34-positive chronic myeloid leukaemia cells increases the selection of Ph-negative cells. Br. J. Haematol. 98: 467.
129. Lynch D H, Andreasen A, Maraskovsky E, Whitmore J, Miller R E, Schuh J C. 1997. FLT3 ligand induces tumor regression and anti-tumor immune responses in vivo. Nature Medicine 3: 625.
130. Chen K, Braun S, Lyman S, Fan Y, Traycoff C M, Wiebke E A, Gaddy J, Sledge G, Broxmeyer H E, Cornetta K. 1997. Anti-tumor activity and immunotherapeutic properties of FLT3 ligand in a murine breast cancer model. Cancer Res. 57: 3511.
131. Molineux G, McCrea C, Yan X Q, Kerzic P, McNiece I. 1997. FLT3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 89: 3998.
132. Sudo Y, Shimazaki C, Ashihara E, Kikuta T, Hirai H, Sumikuma T, Yamagata N, Goto H, Inaba T, Fujita N, Nakagawa M. 1997. Synergistic effect of FLT3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stern cells and progenitor cells into blood in mice. Blood 89: 3186.
133. Brasel K, McKenna H J, Charrier K, Morrissey P J, Williams D E, Lyman S D. 1997. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 90: 3781.
134. Papayannopoulou T, Nakumoto B, Andrews R G, Lyman S D, Lee M Y. 1997. In vivo effects of Flt3/FlK2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor. Blood 90: 620.
135. Juan T S, McNiece I K, Van G, Lacey D, Hartley C, McElroy P, Sun Y, Argento J, Hill D, Yan X Q, Fletcher F A. 1997. Chronic expression of murine FLT3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis. Blood 90: 76.
136. Maraskovsky E, Roux E, Teepe M, Braddy S, Hoek J, Lebsack M, McKenna H J. 1997. FLT3 ligand increases peripheral blood dendritic cells in healthy volunteers. ASH Meeting: 2585.
137. Williams D E. 1997. In vivo effects of flt3 ligand. Blood 90: 5022.
138. Brasel K, McKenna H J, Morrisey P J, Charrier K, Morris A E, Lee C C, Williams D E, Lyman S D. 1996. Hematologie effects of flt3 ligand in vivo in mice. Blood 88: 2004.
139. Liu F, Poursine-Laurent J, Link D C. 1997. The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin-8 but not Flt3 ligand. Blood 90: 2522.
140. Elwood N J, Zogos H, Willson T, Begley C G. 1996. Retroviral transduction of human progenitor cells: use of granulocyte colony-stimulating factor plus stem cell factor to mobilize progenitor cells in vivo and stimulation by Flt3/Flt2 ligand in vitro. Blood 88: 4452.
141. Lebsack M E, Hoek J A, Maraskovsky E, McKenna H J. 1997. Flt3 ligand induces stem and dendritic cell mobilization in healthy volunteers. Proceedings of ISHAGE Meeting: 49.
142. Moore J G, Hata Y S, Chrispeels M J, Witte L D, Feldman M. 1997. Preservation of hematopoietic progenitors for prolonged periods in suspension cultures by FltK2/Flt3 receptor-interacting lectin (FRIL), a new lectin identified in red kidney beans. ASH Meeting: 1899.
143. Kahn L E, Farese A M, Mac Vittie T J, Strauss-Shoenberger J M, Minster N I, Lind L B, McKearn J P, Streeter P R. 1997. Progenipoietin-G promotes in vivo expansion of hematopoietic progenitor cells in mice and in nonhuman primates. ASH Meeting: 248.
144. Mac Vittie T J, Farese A M, Lind L B, Smith W G, Streeter P, McKearn J P. 1997. Progenipoietin-G stimulates hematopoietic recovery following myelosuppression. ASH Meeting: 2586.